 Amryt Pharma PLC NASDAQ:AMYT, LON:AMYT said it was encouraged by data from an investigator-sponsored study of lomitapide in Familial Chylomicronaemia Syndrome FCS. Expert lipidologists in Italy administered the drug, also known as Juxtapid, or Lojuxta, to 18 people with the genetic disease, which results in elevated triglyceride levels, and brings with it significant risk and disease burden. 